Valeritas (NSDQ:VLRX) touted data today from two new studies of its V-Go wearable insulin delivery device in patients with Type II diabetes.
In one three-month evaluation of 60 people with Type II diabetes, researchers assessed if using V-Go could improve glycemic control in patients who were uncontrolled on prior treatment regimens.
“Poor glycemic control (A1C above 9.0%) places patients at high risk for long-term complications and negatively impacts health care costs. Exploring new treatment options which translate into improved glycemic control can benefit patients and have positive implications for health care costs and utilization,” lead author Dr. Patricia Wu said in prepared remarks.
“In our study, use of V-Go resulted in significant improvement in glycemic control and reduced the percentage of patients poorly controlled and at high risk. Diabetes management can be challenging, and the improvements seen in this study are encouraging and clinically relevant,” she added.
In a second presentation, Valeritas presented work from a prospective pilot study that used continuous glucose monitoring to compare time spent in-range for patients taking three or more insulin injection per day versus time spent in-range after switching to V-Go.
““Understanding the percent of time a patient is within an established blood glucose range is an important measure when evaluating glycemic control,” lead author Dr. Shreya Parikh said. “The goal is always to improve blood glucose time in range without increasing hypoglycemia, and I am pleased to see switching to V-Go for insulin delivery achieved this goal and was preferred by patients over their prior insulin regimens.”
After switching to V-Go, the average time spent in-range for patients climbed by 35%, according to Valeritas, compared to baseline insulin therapy. Six out of seven patients had improved time-in-range measures and in those six patients, the average time spent in-range increased by 49%. Those six patients also saw their insulin use drop from 83 units per day to 56 units per day, on average.
The company’s research was presented at the American Association of Clinical Endocrinologists Annual Scientific & Clinical Congress in Boston, Mass.
“We are excited by the results of these two new studies,” president & CEO John Timberlake said in prepared remarks. “The simple, convenient manner in which V-Go delivers basal-bolus therapy continues to prove clinically beneficial and is patient preferred.”
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.
Your article states “Type II Diabetes”
Roman numerals have not been used for about 10 years when referring to the types of diabetes.
Recommend using type 1 diabetes (T1D) or type 2 diabetes (T2D)